MELBOURNE, Australia, May 2 /PRNewswire-FirstCall/ — Australia’s adult stem cell company, Mesoblast Limited (ASX: MSB; US OTC: MBLTY), today announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or ‘off-the-shelf’, adult stem … Continue reading Phase II ASC Clinical Trials Approved for Texas